ストックスクリーナーアプリを入手
2.59
1.89%
-0.05
前日終値:
$2.64
開ける：
$2.64
24時間の取引高:
967.58K
Relative Volume:
1.56
時価総額：
$256.79M
収益：
$9.01M
当期純損益:
$-99.72M
株価収益率:
-0.5707
EPS:
-4.5381
ネットキャッシュフロー:
$-92.85M
1週間 パフォーマンス:
-11.00%
1か月 パフォーマンス:
-26.21%
6か月 パフォーマンス:
-37.44%
1年 パフォーマンス:
-12.79%
1日の値動き範囲:
$2.52
$2.71
1週間の範囲:
$2.43
$2.93
52週間の値動き範囲:
$2.43
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
名前
X 4 Pharmaceuticals Inc
セクター
電話
857-529-8300
住所
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
2.59 | 256.79M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-10 | 開始されました | Wells Fargo | Overweight |
| 2026-06-02 | 開始されました | Leerink Partners | Outperform |
| 2026-03-09 | 開始されました | Guggenheim | Buy |
| 2025-12-05 | 再開されました | Stifel | Buy |
| 2023-12-12 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 再開されました | B. Riley Securities | Buy |
| 2022-12-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2019-12-18 | 開始されました | ROTH Capital | Buy |
| 2019-12-09 | アップグレード | Citigroup | Neutral → Buy |
| 2019-12-05 | 開始されました | B. Riley FBR | Buy |
| 2019-06-07 | 開始されました | Stifel | Buy |
| 2019-06-05 | 開始されました | Cowen | Outperform |
すべてを表示
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
X4 Pharmaceuticals Secures New $150 Million Term Loan - The Globe and Mail
XFOR: X4 Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
X4 Pharmaceuticals (XFOR) pairs a new loan with an approximately $78.7M debt payoff. - Stock Titan
No voting power is reported by Abigail P. Johnson in X4 Pharmaceuticals (XFOR)'s ownership amendment. - Stock Titan
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo Finance
Form 144 X4 Pharmaceuticals For: 1 October By Investing.com - Investing.com Nigeria
Form 144 X4 Pharmaceuticals For: 1 October By Investing.com - Investing.com UK
Medicenna Therapeutics Corp. (MDNAF) Stock Price, News, Quote & History - ca.finance.yahoo.com
Tax withholding requires a proposed 11,767-share sale by an X4 Pharmaceuticals (XFOR) officer. - Stock Titan
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals, Inc. (XFOR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround - Yahoo Finance
Over 5.5M shares in X4 Pharmaceuticals (XFOR) now held by one investor group - Stock Titan
Assembly Biosciences (Nasdaq:ASMB)Stock Analysis - Simply Wall Street
X4 Pharmaceuticals, Inc. (XFOR) Latest Stock News & Headlines - Yahoo Finance
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook By Investing.com - Investing.com India
XFOR: Phase III enrollment for mavorixafor nears completion, with data and launch expected by early 2029 - TradingView
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
X4 Pharmaceuticals (NASDAQ: XFOR) Secures FDA Approval for Reduced Sample Size in 4WARD Trial, Data Expected in Early 2028 - Kalkine Media
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - markets.businessinsider.com
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - The Manila Times
Wells Fargo’s healthcare conference will include an X4 Pharmaceuticals talk Sept. 10 - Stock Titan
X4 Pharmaceuticals Advances Mavorixafor Strategy in Chronic Neutropenia - TipRanks
X4 posts updated corporate presentation; full 4WARD enrollment expected Q4 2026, topline data H1 2028 - TradingView
X4 Pharmaceuticals (XFOR) outlines path to possible 2029 FDA approval - Stock Titan
X4 Pharmaceuticals: FDA OKs Reduced Sample Size for 4WARD Phase 3, Enrollment to Finish by Year-End 2026 - TradingView
FDA backs smaller late-stage test of X4 (NASDAQ: XFOR) neutropenia drug, with pivotal data not due until 2028 - Stock Titan
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting - Yahoo Finance
X4 Pharmaceuticals (XFOR) Plunges 17% as Stock Approaches Critical SupportContinuation Pattern Picks - careplusvn.com
X4 Pharmaceuticals (XFOR) Plunges 17% as Stock Approaches Critical SupportETF NAV Deviation - dars.gov.et
X4 Pharmaceuticals (XFOR) Plunges 17% as Stock Approaches Critical SupportRTH Profile - dars.gov.et
X4 Pharmaceuticals (NasdaqCM:XFOR) Stock Forecast & Analyst Predictions - Simply Wall Street
X4 Pharmaceuticals (XFOR) Plunges 17% as Stock Approaches Critical SupportMFI Overbought - www.dars.gov.et
X4 Pharmaceuticals Stock Price Forecast. Should You Buy XFOR? - StockInvest.us
ETFs Investing in X4 Pharmaceuticals, Inc. Stocks - tradingview.com
X4 Pharmaceuticals Inc. (XFOR) Peer Comparison – Compare with Others - Value Research
Camp4 CFO Kelly Gold buys $39,600 in company stock - investing.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New hires get 50,000 stock options from X4 Pharmaceuticals - Stock Titan
X4 Pharmaceuticals Inc. (XFOR) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView
X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha
X 4 Pharmaceuticals Inc (XFOR) 財務データ
収益
当期純利益
現金流量
EPS
X 4 Pharmaceuticals Inc (XFOR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| David Kirske | Officer |
Oct 01 '26 |
Proposed Sale |
2.86 |
11,767 |
33,658 |
0 |
| Craig Adam R | Executive Chairman |
Aug 12 '26 |
Sale |
4.44 |
47,436 |
210,829 |
328,651 |
| Adam Craig | Executive Chaiman |
Aug 12 '26 |
Proposed Sale |
4.56 |
47,436 |
216,071 |
0 |
| John Volpone | Officer |
Aug 12 '26 |
Proposed Sale |
4.55 |
24,576 |
111,944 |
0 |
| Volpone John | President |
Aug 12 '26 |
Sale |
4.44 |
24,576 |
109,228 |
265,305 |
| KIRSKE DAVID | Chief Financial Officer |
Jun 30 '26 |
Sale |
4.26 |
8,543 |
36,428 |
167,750 |
| David Kirske | Officer |
May 12 '26 |
Proposed Sale |
4.29 |
16,961 |
72,820 |
0 |
| KIRSKE DAVID | Chief Financial Officer |
May 12 '26 |
Sale |
4.29 |
16,961 |
72,820 |
176,293 |
| Craig Adam R | Executive Chairman |
Oct 23 '25 |
Buy |
2.90 |
86,206 |
249,997 |
376,087 |
4.22%
大文字化:
|
ボリューム (24 時間):